One passed its critical trial. One failed it in 2007 and was quietly shelved. This isn't close.
Bottom line: Semaglutide wins by a landslide , 14–15% body weight loss in large RCTs vs. AOD-9604 showing no significant difference from placebo in its Phase 2b trial. AOD-9604's only advantage is its side-effect profile, which is clean primarily because it barely works. The only legitimate case for AOD-9604 is someone with very modest fat-loss goals who absolutely cannot tolerate any GI effects , and even then, the evidence says to expect little.
| AOD-9604 | Semaglutide | |
|---|---|---|
| Category | HGH Fragment 176-191 , synthetic lipolytic domain of growth hormone | GLP-1 receptor agonist , incretin mimetic |
| Mechanism | Binds fat cell receptors to stimulate lipolysis and inhibit lipogenesis; no effect on IGF-1, insulin, or glucose | Activates GLP-1 receptors in brain and gut , suppresses appetite, slows gastric emptying, improves insulin sensitivity |
| Reported dose | 250–500 mcg/day subcutaneous injection | 0.25 mg/week (start) titrating to 2.4 mg/week (max); or 3–25 mg/day oral (Rybelsus) |
| Frequency | Daily injection, typically fasted AM or pre-workout | Once weekly injection; or once daily oral |
| Weight loss in trials | No significant difference from placebo in critical Phase 2b RCT (n=536, 24 weeks); program abandoned 2007 | 14.9% mean body weight loss at 68 weeks (STEP 1, n=1,961); sustained at 15.2% at 2 years (STEP 5) |
| Top side effect | Injection site irritation , adverse events comparable to placebo across all trials; no serious adverse events attributed to compound | Nausea (~37%), vomiting (~24%), diarrhea (~30%) , worst in first 4–8 weeks at each dose increase; typically resolves |
| Effect on appetite | None , does not act on appetite pathways | Strong central appetite suppression plus reduced food reward signaling ('food noise' reduction) |
| IGF-1 / insulin impact | None detected across trials , designed specifically to avoid systemic growth hormone effects | Improves insulin sensitivity; reduces fasting glucose; lowers HbA1c in diabetics |
| Cardiovascular data | None | 20% MACE reduction vs placebo (SELECT, n=17,604) , FDA expanded Wegovy's indication to include CV risk reduction in March 2024 |
| Approval status | Not FDA-approved. TGA-listed in Australia as a food ingredient (no therapeutic claim, no Rx). Clinical development abandoned by originator 2007. | FDA-approved: Ozempic (T2 diabetes, 2017), Wegovy (obesity + CV risk, 2021/2024), Rybelsus (oral T2 diabetes, 2019) |
| Evidence tier | Tier 1 , ran proper RCTs but failed them. Not Tier 3 guesswork; a Tier 1 negative result. | Tier 1 , gold standard. Multiple Phase 3 RCTs, FDA approval, long-term cardiovascular outcome data. |
| Common vial size | 5 mg vials (research vendors); sometimes 10 mg | 5 mg or 10 mg vials (compounded); pre-filled branded pens (Wegovy/Ozempic) |
tierA: {"tier":1,"label":"Phase 2b RCT , failed to beat placebo (n=536)"}
tierB: {"tier":1,"label":"Multiple Phase 3 RCTs, FDA-approved, 17,000+ person cardiovascular trial"}
summary: Both peptides have Tier 1 human trial data, but the outcomes are opposite. AOD-9604 ran a well-designed 24-week RCT (n=536) and failed to demonstrate clinically meaningful weight loss versus placebo , the company shelved the program in 2007. Semaglutide's STEP program produced 14.9% mean weight loss at 68 weeks in STEP 1, and the SELECT trial (n=17,604) confirmed a 20% reduction in major cardiovascular events. The evidence base isn't even in the same league.
trials: [{"name":"AOD-9604 Phase 2a , 12-week obese adults (Metabolic Pharmaceuticals)","peptide":"a","n":"300","finding":"1 mg/day group lost 2.8 kg vs 0.8 kg placebo over 12 weeks , signal appeared but was non-dose-dependent and did not replicate in the larger trial.","pmid":"15134286"},{"name":"AOD-9604 Phase 2b , 24-week critical RCT","peptide":"a","n":"536","finding":"No significant weight loss versus placebo across all dose arms; Metabolic Pharmaceuticals discontinued the program in 2007.","pmid":"17212789"},{"name":"STEP 1 , Once-Weekly Semaglutide 2.4 mg in Adults with Obesity (NEJM 2021)","peptide":"b","n":"1961","finding":"Semaglutide 2.4 mg produced mean 14.9% body weight loss at 68 weeks vs 2.4% with placebo; 86.4% of participants lost ≥5%.","pmid":"33567185"},{"name":"STEP 5 , Two-year effects of semaglutide (Nature Medicine 2022)","peptide":"b","n":"304","finding":"Weight loss sustained at 15.2% at 104 weeks with continued semaglutide 2.4 mg; regained substantially within one year of stopping.","pmid":"36216945"},{"name":"SELECT , Semaglutide cardiovascular outcomes in overweight/obese adults without diabetes (NEJM 2023)","peptide":"b","n":"17604","finding":"Semaglutide 2.4 mg reduced three-point MACE (CV death, MI, stroke) by 20% vs placebo over ~39 months; first weight-loss drug to show a CV mortality benefit.","pmid":"37937763"}]
{"applies":true,"name":"AOD-9604 + Semaglutide","intro":"Some people add AOD-9604 to semaglutide hoping to layer direct adipose lipolysis on top of appetite suppression. Mechanistically non-overlapping , sema works centrally and via gut, AOD works peripherally on fat cells , so there's no pharmacokinetic conflict. Practically, though: if semaglutide is working, you're adding a compound with a failed efficacy record. The incremental benefit is unproven and the added daily injection is real friction. The only coherent case is as a bridging compound during a semaglutide break or micro-dose phase, or for someone specifically wanting to target localized fat without increasing GI burden.","phases":[{"name":"Titration / Acclimation","weeks":"1–8","a":"250 mcg/day subcutaneous, fasted AM , establish baseline, monitor injection site; don't add AOD until sema GI effects are stabilized","b":"0.25 mg/week → 0.5 mg/week per standard titration; manage GI symptoms first before layering in AOD"},{"name":"Maintenance","weeks":"9–24","a":"300–500 mcg/day subcutaneous , no evidence higher doses outperform lower ones; 300 mcg is a reasonable ceiling","b":"1.0–2.4 mg/week depending on tolerance and goal; semaglutide is doing essentially all the metabolic work at this point"}],"note":"This stack is not well-studied. The honest answer is that semaglutide is doing essentially all the work. Adding AOD-9604 adds ~$80–120/month, a daily injection, and an unproven compound to an already-effective protocol. Most people running this combination would get equivalent results from semaglutide alone."}
Yes, but only in the Phase 2a (smaller, 12-week study): the 1 mg/day group lost 2.8 kg vs 0.8 kg on placebo. That looked promising in 2004. Then the proper critical trial ran , 536 people, 24 weeks, double-blind , and it didn't beat placebo. That's how drug development works: a small signal that fails replication means the compound doesn't work reliably enough to matter.
No known pharmacological interaction , mechanisms don't overlap, so it's not dangerous in theory. But you're adding a failed compound to a working one. If sema is doing its job, AOD-9604 adds unproven marginal benefit, a daily injection, and extra cost. Save your pins unless you have a very specific reason.
Three reasons: genuinely clean safety profile (adverse events equal to placebo in trials), much lower cost vs GLP-1s, and pre-2007 hype that still circulates in peptide communities. Some also use it specifically because it won't suppress appetite or affect hormones , they want targeted fat-cell lipolysis only. The evidence doesn't support it for meaningful fat loss, but the risk profile is low enough that people experiment anyway.
No , it's a prescription medication everywhere. Before early 2026, compounding pharmacies could provide it loosely due to an FDA-declared shortage. That shortage officially ended in February 2026, so compounders now require documented clinical justification. Research-vendor 'peptide semaglutide' exists but is legally gray and quality is unverified.
Most people do. The STEP 1 extension showed participants regained roughly 11.6 percentage points of body weight within one year of stopping. Semaglutide manages obesity as a chronic condition , it's not a one-time treatment. AOD-9604 has no data on weight maintenance post-discontinuation because it didn't produce meaningful loss to begin with.
Yes. Explicitly listed under WADA S2.2 (growth hormone fragments) , banned both in and out of competition and detectable in urine. Semaglutide is only on WADA's monitoring list in 2025, not yet banned, but athletes should watch this space heading into 2028.
AOD-9604 is cheap, but it's cheap because it doesn't reliably work. Better options to explore first: Novo Nordisk's Wegovy savings card (can bring cost under $100/month for eligible patients), compounded tirzepatide (often similar pricing to sema with better outcomes), or telehealth platforms with GLP-1 programs. AOD-9604 should be a last resort, not a budget substitute.
Yes , and this is what sets it apart from every other compound in this category. The SELECT trial (17,604 people, ~40 months) showed a 20% reduction in major cardiovascular events , heart attacks, strokes, CV death , independent of how much weight participants lost. The FDA expanded Wegovy's indication to include CV risk reduction in March 2024. No other weight-loss peptide or drug has this data.
These statements have not been evaluated by the FDA. This content is for educational purposes only. Consult a healthcare professional before starting any protocol. vialprep sells injection supplies, not compounds.
